Stoke Therapeutics
Stock Forecast, Prediction & Price Target
Stoke Therapeutics (STOK) stock Price Target by analysts
$18
Potential downside: -1.63%
Stoke Therapeutics price prediction
What is Stoke Therapeutics stock analysts` prediction?
Stoke Therapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Stoke Therapeutics in the last 3 months, the avarage price target is $18, with a high forecast of $NaN. The average price target represents a -1.63% change from the last price of $18.3.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Stoke Therapeutics stock Price Target by analysts
Full breakdown of analysts given Stoke Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Marc Goodman Leerink Partners | 0% 0/1 | 12 months ago | $18 -1.63% downside | $11.84 | TheFly | Previous targets (0) |
Debjit Chattopadhyay H.C. Wainwright | 0% 0/1 | about 1 year ago | $35 91.25% upside | $15.32 | StreetInsider | Previous targets (0) |
Sumant Kulkami Canaccord Genuity | 0% 0/2 | over 1 year ago | $20 9.28% upside | $11.87 | StreetInsider | Previous targets (1) |
Sumant Kulkami Canaccord Genuity | 0% 0/2 | over 1 year ago | $21 14.75% upside | $10.92 | StreetInsider | Previous targets (1) |
Joseph Stringer Needham | 0% 0/1 | over 1 year ago | $22 20.21% upside | $6.5 | StreetInsider | Previous targets (0) |
Unknown Needham | N/A | almost 3 years ago | $25 36.61% upside | $9.33 | Benzinga | N/A |
Judah Frommer Credit Suisse | 0% 0/1 | over 4 years ago | $58 216.93% upside | $32.5 | TheFly | Previous targets (0) |
Stoke Therapeutics Financial Estimates
Stoke Therapeutics Revenue Estimates
Stoke Therapeutics EBITDA Estimates
Stoke Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $12.40M 0% | $8.78M -29.22% | Avg: $16.31M Low: $12.77M High: $22.33M avg. 85.86% | Avg: $26.18M Low: $17.74M High: $32.55M avg. 60.48% | Avg: $81.65M Low: $55.32M High: $101.50M avg. 211.78% | Avg: $159.81M Low: $108.27M High: $198.66M avg. 95.71% |
Net Income
% change YoY
| $-84.71M N/A | $-93.11M -9.91% | $-104.69M -12.44% | Avg: $-143.27M Low: $-150.90M High: $-99.86M avg. -36.84% | Avg: $-153.53M Low: $-125.00M High: $-84.91M avg. -7.16% | Avg: $-78.31M Low: $-103.05M High: $-45.48M avg. 48.99% | Avg: $-36.07M Low: $-47.47M High: $-20.95M avg. 53.93% |
EBITDA
% change YoY
| $-86.06M N/A | $-104.35M -21.25% | $-112.30M -7.61% | Avg: $3.26M Low: $2.55M High: $4.46M avg. 102.90% | Avg: $5.23M Low: $3.54M High: $6.51M avg. 60.48% | Avg: $16.33M Low: $11.06M High: $20.30M avg. 211.78% | Avg: $31.96M Low: $21.65M High: $39.73M avg. 95.71% |
EPS
% change YoY
| -$2.31 N/A | -$2.39 -3.46% | -$2.38 0.41% | Avg: -$2.61 Low: -$3.43 High: -$2.27 avg. -9.63% | Avg: -$2.43 Low: -$2.84 High: -$1.93 avg. 6.86% | Avg: -$1.78 Low: -$2.34 High: -$1.03 avg. 26.75% | Avg: -$0.82 Low: -$1.08 High: -$0.48 avg. 53.93% |
Operating Expenses
% change YoY
| $86.06M N/A | $116.76M 35.66% | $123.55M 5.81% | Avg: $34.55M Low: $27.04M High: $47.28M avg. -72.03% | Avg: $55.45M Low: $37.57M High: $68.93M avg. 60.48% | Avg: $172.89M Low: $117.13M High: $214.92M avg. 211.78% | Avg: $338.37M Low: $229.25M High: $420.63M avg. 95.71% |
FAQ
What is Stoke Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 14.73% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -150.90M, average is -143.27M and high is -99.86M.
What is Stoke Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 113.46% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $12.77M, average is $16.31M and high is $22.33M.
What is Stoke Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 19.47% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$3.43, average is -$2.61 and high is $-2.27.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Stoke Therapeutics stock. The most successful analyst is Marc Goodman.